• PureTech Health noted Seaport Therapeutics reported positive Phase 1 repeat-dose results for GlyphAgo, supporting continued development.
• Findings were presented now; additional Phase 1 analyses are slated for future scientific meetings.
• Repeat dosing showed a favorable safety and tolerability profile, with no liver-related adverse events reported.
• Data support planned Phase 2 studies in generalized anxiety disorder, including a Phase 2a start in H2 2026 with topline data expected in early 2028.
• A Phase 2b trial is planned to start in H1 2027, with topline results expected by end-2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PureTech Health plc published the original content used to generate this news brief via Business Wire (Ref. ID: 20260608428399) on June 09, 2026, and is solely responsible for the information contained therein.